Browse All Grants
20,252 grants found
Showing 2,121 – 2,140 of 20,252 grants
Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage
Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects o...
Administrative Core
The Administrative Core is led by the U54’s Principal Investigators, Ernest Martinez, Ph.D. (PI, University of California, Riverside [UCR]) and Victoria Seewaldt, M.D. (PI, City of...
Capacity Development Core
It is challenging to build successful research collaborations. Successful collaborations are even more challenging when working across institutions and with early-stage investigato...
Full Project 1
Most luminal B breast cancers (LBBC; ER+, HER2-wt, Ki67>14%) carry a good prognosis. However, approximately 20% of LBBC are highly aggressive and resistant to current therapies....
Full Project 2
PIN1 is a cis-trans prolyl isomerase that controls proline-mediated phosphorylation signaling events that is overexpressed both in pancreatic cancer cells and cancer-associated fib...
Pilot-Project 1
University of California, Riverside (UCR) has never implemented a therapeutic trial. Building therapeutic trial capacity at UCR was our biggest challenge – and the biggest failure...
Planning & Evaluation
The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The...
Research Education
Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long...
Outreach
Our U54 Outreach Core will facilitate the successful translation, implementation, and dissemination of research findings developed by U54 investigators. We build on the community r...
A Patient-Centric Approach to Advance Functional Precision Oncology
PROJECT SUMMARY/ABSTRACT The development of drug resistance is a major cause of cancer treatment failure and mortality. Although much is known about the mechanisms by which tumor c...
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
The United States (U.S.) has led the world in drug discovery for over 50-years. While this is a significant accomplishment, U.S. drugs have been almost exclusively optimized and te...
Administrative Core
The Administrative Core is led by the U54’s Principal Investigators, Ernest Martinez, Ph.D. (PI, University of California, Riverside [UCR]) and Victoria Seewaldt, M.D. (PI, City of...
Core 4: Shared Resource - Capacity Development
It is challenging to build successful research collaborations. Successful collaborations are even more challenging when working across institutions and with early-stage investigato...
Project 1
Most luminal B breast cancers (LBBC; ER+, HER2-wt, Ki67>14%) carry a good prognosis. However, approximately 20% of LBBC are highly aggressive and resistant to current therapies....
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
The United States (U.S.) has led the world in drug discovery for over 50-years. While this is a significant accomplishment, U.S. drugs have been almost exclusively optimized and te...
Administrative Core
The Administrative Core is led by the U54’s Principal Investigators, Ernest Martinez, Ph.D. (PI, University of California, Riverside [UCR]) and Victoria Seewaldt, M.D. (PI, City of...
Project 2
PIN1 is a cis-trans prolyl isomerase that controls proline-mediated phosphorylation signaling events that is overexpressed both in pancreatic cancer cells and cancer-associated fib...
Capacity Development Core
It is challenging to build successful research collaborations. Successful collaborations are even more challenging when working across institutions and with early-stage investigato...
Pilot Project 1
University of California, Riverside (UCR) has never implemented a therapeutic trial. Building therapeutic trial capacity at UCR was our biggest challenge – and the biggest failure...
Full Project 1
Most luminal B breast cancers (LBBC; ER+, HER2-wt, Ki67>14%) carry a good prognosis. However, approximately 20% of LBBC are highly aggressive and resistant to current therapies....